» Articles » PMID: 31426679

Is There a Role for Carbon Therapy in the Treatment of Gynecological Carcinomas? A Systematic Review

Overview
Journal Future Oncol
Specialty Oncology
Date 2019 Aug 21
PMID 31426679
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

This Systematic Review summarizes the literatures of clinical trials on the efficacy and safety of carbon ion therapy for gynecological carcinomas. The protocol is detailed in the online PROSPERO database, registration no. CRD42019121424, and a final set of eight studies were included. In the treatment of cervical carcinomas, both carbon ion therapy alone and carbon ion therapy concurrent chemotherapy have presented good efficacy. Besides, the efficacy of inoperable endometrial carcinomas and gynecological melanoma are similar to that of surgical treatment. In terms of safety, gastrointestinal and genitourinary toxicities are low and could be controlled by limiting the volume and dose of intestinal tract and bladder. Carbon ion radiotherapy could be considered a safe, effective and feasible therapy for gynecological carcinomas.

Citing Articles

The first real-world study on the role of carbon ion radiotherapy for oligo-metastatic, persistent, or recurrent (MPR) ovarian/fallopian tube cancer.

Barcellini A, Murata K, Fontana G, Vai A, Cassani C, Landoni F Clin Transl Radiat Oncol. 2024; 47:100781.

PMID: 38726346 PMC: 11081775. DOI: 10.1016/j.ctro.2024.100781.


A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results.

Okonogi N, Murata K, Yamada S, Habu Y, Hori M, Kurokawa T Int J Mol Sci. 2023; 24(13).

PMID: 37445743 PMC: 10342070. DOI: 10.3390/ijms241310565.


Secondary cancers after carbon-ion radiotherapy and photon beam radiotherapy for uterine cervical cancer: A comparative study.

Nitta Y, Murata H, Okonogi N, Murata K, Wakatsuki M, Karasawa K Cancer Med. 2022; 11(12):2445-2454.

PMID: 35318825 PMC: 9189463. DOI: 10.1002/cam4.4622.


Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study.

Okonogi N, Usui H, Murata K, Hori M, Kurokawa T, Fujiwara T BMJ Open. 2022; 12(3):e056424.

PMID: 35236732 PMC: 8896055. DOI: 10.1136/bmjopen-2021-056424.


Carbon ion radiotherapy for bladder cancer: A case report.

Zhang Y, Li X, Zhang Y, Hu T, Chen W, Pan X World J Clin Cases. 2021; 9(26):7833-7839.

PMID: 34621834 PMC: 8462265. DOI: 10.12998/wjcc.v9.i26.7833.